Forian (FORA) Stock Price, News & Analysis

Company Overview

Forian Inc. provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions. The company's subscription and services-based solutions cover the life sciences, pharma services, and healthcare payer and provider industries. Forian Inc. was founded in 2020 and is headquartered in Newtown, Pennsylvania.

Key Stats

• Today's Range: $2.01 to $2.25
• 50-Day Range: $1.86 to $2.24
• 52-Week Range: $1.85 to $4.03
• Volume: 15,755 shs
• Average Volume: 16,653 shs
• Market Capitalization: $66.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Forian Stock Analysis - MarketRank™

Forian scored higher than 54% of companies evaluated by MarketBeat, and ranked 508th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Forian has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Forian has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Forian is -23.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Forian is -23.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.63% of the float of Forian has been sold short.

Short Interest Ratio / Days to Cover

Forian has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Forian has recently decreased by 10.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Forian does not currently pay a dividend.

Dividend Growth

Forian does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.63% of the float of Forian has been sold short.

Short Interest Ratio / Days to Cover

Forian has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Forian has recently decreased by 10.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Forian has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Forian this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Forian insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.30% of the stock of Forian is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 19.25% of the stock of Forian is held by institutions.

FORA Stock Analysis - Frequently Asked Questions

How have FORA shares performed this year?

Forian's stock was trading at $2.06 on January 1st, 2025. Since then, FORA stock has increased by 3.4% and is now trading at $2.13.
View the best growth stocks for 2025 here.

How were Forian's earnings last quarter?

Forian Inc. (NASDAQ:FORA) posted its earnings results on Wednesday, May, 14th. The company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.06. The business had revenue of $7.06 million for the quarter, compared to analysts' expectations of $5.37 million.
Read the conference call transcript.

Who are Forian's major shareholders?

Top institutional investors of Forian include Canton Hathaway LLC (0.79%). Insiders that own company stock include Max C Wygod, Stanley S Trotman Jr and Martin J Wygod.
View institutional ownership trends.

How do I buy shares of Forian?

Shares of FORA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Forian own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Forian investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), PayPal (PYPL), Taiwan Semiconductor Manufacturing (TSM), IAMGOLD (IAG) and XPeng (XPEV).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 8/13/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:FORA
• CIK: 1829280
• Web: forian.com
• Phone: +17203285372
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +134.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $22.33 million
• Price / Sales: 2.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 31,202,000
• Free Float: N/A
• Market Cap: $66.46 million
• Optionable: Optionable
• Beta: 1.03